These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23142439)

  • 1. Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial.
    Scott DF; Woltz JN; Smith RR
    J Arthroplasty; 2013 Apr; 28(4):671-5. PubMed ID: 23142439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
    Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: A randomized placebo-controlled trial of women undergoing total hip arthroplasty.
    Aro E; Moritz N; Mattila K; Aro HT
    J Biomech; 2018 Jun; 75():35-45. PubMed ID: 29747966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone Remodelling in the Proximal Femur after Uncemented Total Hip Arthroplasty in Patients with Osteoporosis].
    Lacko M; Schreierová D; Čellár R; Vaško G
    Acta Chir Orthop Traumatol Cech; 2015; 82(6):430-6. PubMed ID: 26787184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
    D'Souza AB; Grigg AP; Szer J; Ebeling PR
    Intern Med J; 2006 Sep; 36(9):600-3. PubMed ID: 16911552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial.
    Muren O; Akbarian E; Salemyr M; Bodén H; Eisler T; Stark A; Sköldenberg O
    Acta Orthop; 2015; 86(5):569-74. PubMed ID: 25885280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
    Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
    BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
    Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
    Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
    Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R; Gesztesi Z; Rochford J
    Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.